1315
In the two cases, a combination of iloprost, a stable prostacyclin analogue (1 to 2 ng/kg/mn) with aspirin and dipyridamole was shown to inhibit ex vivo the heparin-induced platelet aggregation.
 two cases: Subject; two: Subject.Population; iloprost, a stable prostacyclin analogue (1 to 2 ng/kg/mn) with aspirin and dipyridamole: Treatment; heparin-induced platelet aggregation: Treatment.Disorder; 1 to 2 ng/kg/mn: Treatment.Dosage; iloprost: Treatment.Drug; aspirin: Treatment.Drug; dipyridamole: Treatment.Drug; iloprost: Combination.Drug; aspirin: Combination.Drug; dipyridamole: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 two cases: Subject; two: Subject.Population; iloprost, a stable prostacyclin analogue (1 to 2 ng/kg/mn) with aspirin and dipyridamole: Treatment; heparin-induced platelet aggregation: Treatment.Disorder; 1 to 2 ng/kg/mn: Treatment.Dosage; iloprost: Treatment.Drug; aspirin: Treatment.Drug; dipyridamole: Treatment.Drug; iloprost: Combination.Drug; aspirin: Combination.Drug; dipyridamole: Combination.Drug